76results about "Cis-trans-isomerases" patented technology

The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present invention concerns the use of peptidyl-prolyl isomerase cyclophilin 40 (CyP40) for reduction of neurotoxic fibrils and treatment and prevention of neurodegenerative diseases associated with amyloid fibril aggregation. Aspects of the invention include compositions, methods, dosage forms, and kits for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation in a human or animal subject, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using CyP40, or a biologically active fragment thereof.

The present invention relates to means and methods for optimizing expression of a heterologous polypeptide of interest in Gram-positive host cells by co-expression with a foldase that is cognate to the heterologous polypeptide of interest.

The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.

The present disclosure generally relates to compositions and methods for constructing and / or obtaining B. licheniformis cells (e.g., protein-producing hosts) that comprise enhanced protein production capabilities. Accordingly, certain embodiments relate to genetically modified B. licheniformis strains derived from a parent Bacillus licheniformis strain that produce increased amounts of one or more proteins of interest.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

This invention relates to the field of biotechnology, and more particularly to the tobacco NtD27 gene and its applications. Through research on the NtD27 gene, this application has discovered that this gene affects the development of tobacco axillary buds. Knockout mutations of the NtD27 gene can promote the growth of tobacco axillary buds, while overexpression of the NtD27 gene can effectively inhibit the growth of tobacco axillary buds. This provides potential germplasm resource support for molecular breeding of tobacco with fewer axillary buds and has significant practical value in the genetic improvement of important traits in tobacco and in basic botanical research.

The invention relates to a bacillus licheniformis host cell for increasing production of secretory protein. In particular, the present invention relates to a Bacillus licheniformis host having a genetic modification that results in an increased production of heterologous, non-natural, secretory enzymes. Specifically, the present invention relates to a Bacillus licheniformis host cell which expresses a) a first polypeptide having peptidyl-prolyl cis-trans isomerase (EC 5.2. 1.8) activity comprising the amino acid sequence as shown in SEQ ID NO: 1, or at least 81% identical to SEQ ID NO: 1, and b) a second polypeptide having amylase activity comprising the amino acid sequence as shown in SEQ ID NO: 1, or at least 81% identical to SEQ ID NO: 2. Wherein the second polypeptide is heterologous to the Bacillus licheniformis host cell.

The present disclosure provides compositions and methods related to transcription factor systems. Such systems provide modular and tunable protein expression driven by regulated transcriptional activity.

This application relates to a mutant prolyl isomerase and a method for producing glutamate series amino acids using the same.

The present invention provides methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells. The present invention provides methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.

The invention discloses a phoebe bournei constitutive high-expression promoter and application of the phoebe bournei constitutive high-expression promoter in gene expression regulation, and relates to the technical field of plant molecular biology. The nucleotide sequence of the phoebe bournei constitutive high-expression promoter PbCYPpro disclosed by the invention is shown as SEQ ID NO.4. The expression abundance and GUS dyeing effect of a target gene mediated by the promoter PbCYPpro of a PbCYP gene are compared and analyzed, and the drive expression capability of the promoter is found to be remarkably higher than that of a 35S promoter, so that the promoter can replace an exogenous constitutive promoter to improve the expression level of the target gene in a plant body; meanwhile, the transgenic screening efficiency is remarkably optimized, support is provided for efficient expression of Cas protein in a CRISPR gene editing system, and the editing success rate is greatly increased. According to the promoter provided by the invention, the genetic engineering technology blank of the endangered tree species phoebe bournei is filled for the first time, and a core tool is provided for molecular breeding and resource protection.

The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers.

The present disclosure relates to engineered depalmitoylases. S-Palmitoylation is a reversible post-translational modification that tunes the localization, stability, and function of an impressive array of proteins including ion channels, G-proteins, and synaptic proteins. Altered protein palmitoylation is linked to various human diseases including cancers, neurodevelopmental and neurodegenerative diseases. Disclosed herein is an engineered chemogenetic depalmitoylase that manipulates the palmitoylation status of target proteins using a chemically inducible dimerization system. In some aspects, the engineered chemogenetic depalmitoylase is programed to allow selective depalmitoylation in specific organelles, of individual protein complexes, or triggered by cell-signaling events. Also disclosed is an engineered depalmitoylase that allows depalmitoylation of proteins in response to Erk phosphorylation. An optogenetic actuator to manipulate protein palmitoylation is also disclosed. The disclosed engineered depalmitoylases represent versatile and powerful methods for manipulating protein palmitoylation in live cells.

The invention is directed to peptide fragments of FKBP52 that inhibit Tau protein aggregation and ameliorate tauopathies like Alzheimer's Disease (AD). It also involves modifications to these peptides to improve their pharmacokinetic and pharmacodynamic properties.

The present invention relates to methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.

The invention provides an anti-ETEC engineering probiotic as well as a construction method and application thereof, and belongs to the technical field of gene engineering. According to the present invention, lactic acid bacteria are adopted as a presentation vector, a CLA gene coding linoleic acid isomerase in Lactobacillus rhamnosus GG (Lactobacillus rhamnosus) is amplified, and the CLA gene is connected with a Lactobacillus casei ATCC393 (Lactobacillus casei) expression vector pPG 612 so as to construct the engineering bacteria probiotic LC-pPG-CLA; the engineering probiotics have high adhesion and invasion ability to Caco-2 cells, and can competitively inhibit the ETEC K88 strain from adhering to the Caco-2 cells so as to reduce invasion and infection of the ETEC K88 strain to the Caco-2 cells.

The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present invention relates to a Bacillus licheniformis host cell for increased production of secreted proteins. Specifically, the invention relates to a Bacillus licheniformis host with a genetic modification that leads to increased production of a heterologous, non-native, secreted enzyme. Specifically, the present invention relates to a Bacillus licheniformis host cell expressing a) a first polypeptide having peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) activity, said first polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 1, or an amino acid sequence being a least 81% identical to SEQ ID NO: 1, and b) a second polypeptide having amylase activity, wherein said second polypeptide is heterologous to said Bacillus licheniformis host cell.

The invention is applicable to the technical field of gene engineering, and provides a cryptosporidium parvum CpCyP23 deleted strain as well as a construction method and application thereof, the construction method comprises the following steps: a CpCyP23 gene is knocked out by using a CRISPR / Cas9 technology to obtain the cryptosporidium parvum CpCyP23 deleted strain, and the sequence of the CpCyP23 gene is shown as SEQ ID NO: 27. The invention provides the construction method of the cryptosporidium parvum CpCyP23 deleted strain and the CpCyP23 deleted strain constructed by the construction method, and proves that the deletion of the cyclophilin CpCyP23 of the cryptosporidium parvum delays the ectogenesis of the cryptosporidium parvum, and the CpCyP23 deleted strain can reduce the pathogenicity of the cryptosporidium parvum. The result shows that the CpCyP23 is a vaccine target spot for intervening cryptosporidium infection, and the deletion strain of the CpCyP23 can be used as a cryptosporidium vaccine candidate strain.

Provided is a method for the high expression of a recombinant human serum albumin, characterized in comprising the step of co-expressing: (a) a human serum albumin gene, and (b) one or more rHSA expression promoting factor genes in a yeast host cell.

The present invention relates to an activator of the BMP-SMAD signaling pathway or a pharmaceutical composition comprising said modulator, for use in the treatment and / or prevention of muscle atrophy or for use in a method for the promotion and / or induction of muscle hypertrophy.

Provided herein are methods, compositions, kits and systems for regulation of peptide function. In particular, provided herein are methods, compositions, kits and systems comprising nucleic acid constructs and fusion proteins comprising chemically-activated protein domains (CAPs) that regulate the activity of a fused peptide in the presence of a ligand.

The invention discloses a method for improving canker resistance of citrus by using a CsFKBP16-4 gene, and relates to the field of molecular biology, the transcriptional level of the FKBP16-4 gene in citrus plants is reduced by interfering RNA, and the nucleotide sequence of the interfering RNA is as shown in SEQ ID NO: 1. A part of coding sequence of the CsFKBP16-4 gene is used as an interference sequence, is introduced into an interference vector, and is integrated into a citrus genome through an agrobacterium-mediated genetic transformation method, so that the canker resistance of citrus is effectively improved. The canker attack degree of the obtained transgenic plant can be reduced to 28.3% of that of the existing citrus, the canker symptom of the transgenic citrus is remarkably relieved, and the canker resistance of the citrus is improved. In addition, transgenic citrus plants can directly inhibit proliferation of pathogenic bacteria causing canker, the canker can be ensured to be inhibited essentially, another way for citrus canker-resistant breeding is opened up, and development of citrus canker-resistant breeding is promoted.

The present invention belongs to the field of biotechnology, and specifically relates to a biological probe for detecting Pin1 isomerase activity and its application. The biological probe consists of a donor-acceptor pair, a linker, and a Pin1 recognition domain; wherein the donor is a green fluorescent protein called mClover3, and the acceptor is a red fluorescent protein called mRuby3; the recognition domain is a peptide segment containing the potential recognition site Ser / Thr-Pro of Pin1; and the linker is a short peptide rich in hydrophobic amino acid residues. Based on the principle of fluorescence resonance energy transfer, this patent proposes for the first time to use the Ser / Thr-Pro motif as a recognition domain to construct a FRET biological probe that can detect Pin1 isomerase activity in different living cells. This patent not only provides a new method for studying the pathogenesis and early diagnosis of cancer and AD, but can also evolve into a high-throughput screening device for anti-cancer drugs and anti-AD drugs.

The present disclosure relates compositions, systems, and methods for treating, inhibiting, decreasing, reducing, ameliorating, and / or preventing a cancer or a proliferative disease using a selection gene drive therapy.

The present disclosure relates to microbial hosts and methods for biosynthesis of compositions comprising milk fat triglycerides.

The present disclosure relates to methods of modulating FK506-binding protein-51 (FKBP51) mediated glucocorticoid signalling and HSD11B1 expression in uterine disorders. Further disclosed are compositions comprising FKBP5 gene modulating agents and use thereof.